Ankylosing Spondylitis Clinical Trial
Official title:
Research Asistant in Deparment of Nursing
Verified date | September 2020 |
Source | Eskisehir Osmangazi University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study was carried out to develop mobile application on the android platform for the
subcutaneous anti-TNF drug adherence of ankylosing spondylitis patients and to evaluate the
effect of this application on drug compliance.
The universe of this experimental designed posttest control group research is consisted of
patients prescribed subcutaneous anti-TNF drug due to ankylosing spondylitis in Eskişehir
Osmangazi University Health, Application and Research Hospital Rheumatology Polyclinic
between 15 December 2017 - 30 June 2019. The patients who constituted the sample of the study
were assigned by lot to mobile application and the education booklet groups. The mobile
application that includes follow-up and information related to disease information, anti-TNF
drug application and management was transferred to mobile phones of patients in mobile
application group via bluetooth technology and installed. The patients in the education
booklet group were given an education booklet on disease information, antiTNF drug
administration and management. In the study, patients were evaluated once before anti-TNF
drug treatment and every 6 weeks during 6 months (4 times) after treatment. The data of the
study were collected by means of an individual identification form, BASDAI, BASFI, ASQoL and
Subcutaneous Anti-TNF Treatment Adherence Questionnaire.
Status | Completed |
Enrollment | 32 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - are diagnosed with ankylosing spondylitis according to the New York modification criterias - administer anti-TNF agent for the first or second time - are 18 years old and had literacy - have an android phone, - can use the andriod phone, - agree to participate in the work Exclusion Criteria: - refuse to participate in the study - be young than 18 years old - administer anti-TNF agent more than twice |
Country | Name | City | State |
---|---|---|---|
Turkey | Eskisehir Osmangazi University Faculty of Health Sciences | Eskisehir |
Lead Sponsor | Collaborator |
---|---|
Eskisehir Osmangazi University | Koç University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | subcutaneous anti TNF-a drug adherence was assesed by "Subcutaneous Anti-TNF-a Treatment Adherence Questionnaire" | In this questionnaire, It is expected from patients to answer "no" to these questions: "In the last 6 weeks, did you ever miss or forget your dose of medication?" and "Did you ever skip implementing your medication dose thinking that your illness is under control?" The drug adherence of the patients who answered "no" to these questions is considered evaluated as good, and those who answered "yes" to these questions the drug compliance is considered as poor. |
4 times in 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |